These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 23825539

  • 1. Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts.
    Hermann PC, Trabulo SM, Sainz B, Balic A, Garcia E, Hahn SA, Vandana M, Sahoo SK, Tunici P, Bakker A, Hidalgo M, Heeschen C.
    PLoS One; 2013; 8(6):e66371. PubMed ID: 23825539
    [Abstract] [Full Text] [Related]

  • 2. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
    Zhang Y, Liu L, Fan P, Bauer N, Gladkich J, Ryschich E, Bazhin AV, Giese NA, Strobel O, Hackert T, Hinz U, Gross W, Fortunato F, Herr I.
    Oncotarget; 2015 Apr 30; 6(12):9999-10015. PubMed ID: 25846752
    [Abstract] [Full Text] [Related]

  • 3. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
    Rajeshkumar NV, Rasheed ZA, García-García E, López-Ríos F, Fujiwara K, Matsui WH, Hidalgo M.
    Mol Cancer Ther; 2010 Sep 30; 9(9):2582-92. PubMed ID: 20660600
    [Abstract] [Full Text] [Related]

  • 4. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
    Burkhart C, Fleyshman D, Kohrn R, Commane M, Garrigan J, Kurbatov V, Toshkov I, Ramachandran R, Martello L, Gurova KV.
    Oncotarget; 2014 Nov 30; 5(22):11038-53. PubMed ID: 25402820
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
    Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A, Rajeshkumar NV.
    Cancer Lett; 2013 Jul 10; 335(1):41-51. PubMed ID: 23402814
    [Abstract] [Full Text] [Related]

  • 7. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment.
    Liu Q, Wu H, Li Y, Zhang R, Kleeff J, Zhang X, Cui M, Liu J, Li T, Gao J, Pan B, Wu W, Wang W, Zhou L, Guo J, Dai M, Zhang T, Liao Q, Lu Z, Zhao Y.
    Cancer Immunol Immunother; 2020 Aug 10; 69(8):1477-1492. PubMed ID: 32285172
    [Abstract] [Full Text] [Related]

  • 8. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.
    Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M.
    Cancer Treat Rev; 2014 Feb 10; 40(1):118-28. PubMed ID: 23849556
    [Abstract] [Full Text] [Related]

  • 9. Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
    Gitto SB, Pandey V, Oyer JL, Copik AJ, Hogan FC, Phanstiel O, Altomare DA.
    Mol Pharm; 2018 Feb 05; 15(2):369-376. PubMed ID: 29299930
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms.
    Cioffi M, Trabulo S, Hidalgo M, Costello E, Greenhalf W, Erkan M, Kleeff J, Sainz B, Heeschen C.
    Clin Cancer Res; 2015 May 15; 21(10):2325-37. PubMed ID: 25717063
    [Abstract] [Full Text] [Related]

  • 11. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
    Dosch AR, Dai X, Reyzer ML, Mehra S, Srinivasan S, Willobee BA, Kwon D, Kashikar N, Caprioli R, Merchant NB, Nagathihalli NS.
    Mol Cancer Res; 2020 Apr 15; 18(4):623-631. PubMed ID: 31949002
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling.
    Balic A, Sørensen MD, Trabulo SM, Sainz B, Cioffi M, Vieira CR, Miranda-Lorenzo I, Hidalgo M, Kleeff J, Erkan M, Heeschen C.
    Mol Cancer Ther; 2014 Jul 15; 13(7):1758-71. PubMed ID: 24785258
    [Abstract] [Full Text] [Related]

  • 14. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC, Chafe SC, Brown WS, Saberi S, Swayampakula M, Venkateswaran G, Nemirovsky O, Gillespie JA, Karasinska JM, Kalloger SE, Supuran CT, Schaeffer DF, Bashashati A, Shah SP, Topham JT, Yapp DT, Li J, Renouf DJ, Stanger BZ, Dedhar S.
    Gastroenterology; 2019 Sep 15; 157(3):823-837. PubMed ID: 31078621
    [Abstract] [Full Text] [Related]

  • 15. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X, Fan W, Xu Z, Chen H, He Y, Yang G, Yang G, Hu H, Tang S, Wang P, Zhang Z, Xu P, Yu M.
    Oncotarget; 2016 Dec 06; 7(49):81110-81122. PubMed ID: 27835602
    [Abstract] [Full Text] [Related]

  • 16. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.
    Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al-Hallak MN, Tesfaye A, Kim S, Shidham V, M Mohammad R, Philip PA.
    Clin Cancer Res; 2020 Mar 15; 26(6):1338-1348. PubMed ID: 31831564
    [Abstract] [Full Text] [Related]

  • 17. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
    Park JK, Kim Y, Kim H, Jeon J, Kim TW, Park JH, Hwnag YI, Lee WJ, Kang JS.
    Oncotarget; 2016 Nov 15; 7(46):75081-75093. PubMed ID: 27655706
    [Abstract] [Full Text] [Related]

  • 18. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
    Horiuchi T, Uwagawa T, Shirai Y, Saito N, Iwase R, Haruki K, Shiba H, Ohashi T, Yanaga K.
    J Surg Res; 2016 Nov 15; 206(1):1-8. PubMed ID: 27916347
    [Abstract] [Full Text] [Related]

  • 19. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
    Zhuang Z, Li H, Lee H, Aguilar M, Gocho T, Ju H, Iida T, Ling J, Fu J, Wu M, Sun Y, Lu Y, Chiao PJ.
    Cancer Lett; 2017 Dec 28; 411():44-56. PubMed ID: 28951128
    [Abstract] [Full Text] [Related]

  • 20. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.
    Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, Ellwart JW, Mustafa M, Bartenstein P, D'Haese JG, Schoenberg MH, Berger F, Jauch KW, Hidalgo M, Heeschen C.
    Gastroenterology; 2009 Sep 28; 137(3):1102-13. PubMed ID: 19501590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.